Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial)
Summary
CONCLUSIONS Both vaccines were safe but did not show any efficacy against all forms of microbiologically confirmed TB or pulmonary TB. VPM1002 showed considerable efficacy against extrapulmonary TB. Both vaccines showed efficacy against extrapulmonary TB in participants who had a positive tuberculin skin test. TRIAL REGISTRATION Clinical Trials Registry India CTRI/2019/01/017026.
Content
# Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial)
*Published: 2026 Apr 9*
## CONCLUSIONS
Both vaccines were safe but did not show any efficacy against all
forms of microbiologically confirmed TB or pulmonary TB. VPM1002 showed
considerable efficacy against extrapulmonary TB. Both vaccines showed efficacy
against extrapulmonary TB in participants who had a positive tuberculin skin
test.
## TRIAL REGISTRATION
Clinical Trials Registry India CTRI/2019/01/017026.
DOI: 10.1136/bmj-2025-085716